FRONT ONCOL 润色咨询

Frontiers in Oncology

出版年份:2011 年文章数:14479 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:2.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-11-21 清清欢 来自江西省

    偏重的研究方向:肿瘤免疫
    经验分享:这个杂志未来预警的可能性大吗?

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-10-30 小鹏友 来自重庆

    审稿速度:3.0 | 投稿命中率:95.0
    偏重的研究方向:肿瘤
    经验分享:非常水……😌😌😌😌

    5

    展开5条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-10-04 ms1000000556586108 来自湖南省

    技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-11-10 ms4000000828277451 来自山东省

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向:肺癌
    经验分享:非常快!
    27 Sep 2023
    Article accepted for publication.
    Submitting Author re-submitted manuscript.
    25 Sep 2023
    Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.
    Review of Reviewer 2 is finalized.
    Review of Reviewer 1 is finalized.
    13 Sep 2023
    Submitting Author submitted manuscript.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-11-06 ms7000002110969436 来自江苏省

    目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-11-01 1521ae796fm 来自四川省

    有没有投稿网址啊

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2022-05-18 ms2000001171054439

    偏重的研究方向:头颈肿瘤;影像;Oncology
    经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊

    7

    展开7条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-10-13 ms8000001912482889 来自陕西省

    投稿命中率:50.0
    经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-10-10 P拾荒者 来自浙江省

    偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫
    经验分享:FII被拒了,能不能再投这个啊

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向:肿瘤免疫<br>经验分享:这个杂志未来预警的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了,催了几次都说会催诚信团队,但至今都卡在技术审查这步,有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌<br>经验分享:非常快!<br>27 Sep 2023 <br>Article accepted for publication.<br>Submitting Author re-submitted manuscript.<br>25 Sep 2023 <br>Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.<br>Review of Reviewer 2 is finalized.<br>Review of Reviewer 1 is finalized.<br>13 Sep 2023 <br>Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人,且这个审稿人审稿结束了,同意出版。编辑说还要邀请审稿人呢,一个审稿人不行,已经过去半个月了,还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向:头颈肿瘤;影像;Oncology<br>经验分享:请问我的一个个案 ,自我感觉头颈肿瘤和肿瘤影像两部分都可以投,我投了头颈肿瘤,但是现在已经快EA一个月了,我上面至今都没有编辑的名字(没分到编辑),我也写信推荐了(他说我可以推荐一个可能的编辑)。请问各位大佬们,如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试,不行就换杂志了,伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0<br>经验分享:一个月了状态还停留在Initial Validation阶段,催稿也未回复,有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向:非小细胞肺癌;临床;肿瘤免疫<br>经验分享:FII被拒了,能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]
    2023-07-12 gaogao 来自广东省

    请问大家Review Finalized 阶段会多久有结果

    2

    展开2条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分